Skip to main content

Table 3 Summary of computed dosimetry

From: Towards personalised dosimetry in patients with liver malignancy treated with 90Y-SIRT using in vivo-driven radiobiological parameters

Cancer type Dose (Gy) BED \(\infty\) (Gy) BEDexp (Gy) TCP (%) \(\Delta {\text{TLG}}_{{{\text{liver}}}}\)(%)
Breast 47.7 58.0 41.5 41.7 43.6
PNET 51.4 56.8 45.3 44.2 48.8
Adrenocortical carcinoma 52.7 67.7 26.2 17.6 23.7
CRC 127 170 90.1 65.6 75.5
Cholangiocarcinoma 28.1 46.2 46.1 50.6 56.9
CRC 33.3 37.6 6.03 0.12 − 113
CRC 42.6 53.0 43.3 42.8 47.7
Rectal adenocarcinoma 12.3 12.9 12.6 20.4 25.8
Cholangiocarcinoma 34.0 51.3 51.3 82.5 98.6
CRC 33.2 37.0 8.10 0.10 − 9.73
Cholangiocarcinoma 272 554 11.8 7.31 16.0
Cholangiocarcinoma 39.3 74.6 73.6 71.9 82.6
Sigmoid adenocarcinoma 53.0 62.7 61.9 54.6 70.3
Breast 45.6 93.0 93.0 79.1 89.0
Prostate 62.6 107 107 82.0 96.0
mCRC 29.5 34.2 32.7 32.1 37.5
PNET 42.2 60.9 60.7 50.8 57.0
PDAC 8.84 47.8 47.8 45.0 58.3
SBNET 231 368 368 81.3 85.1
Mesothelioma 59.9 62.5 69.9 60.6 65.7
PNET 97.8 116 116 72.8 80.3
HCC 80.6 134 12.5 0.27 0.15
Oesophageal 37.7 63.6 63.5 51.7 62.0
SBNET 50.0 55.1 40.3 31.5 35.0
NEC 17.1 21.9 10.5 0.32 − 2.29
  1. \(\Delta {\text{TLG}}_{{{\text{liver}}}}\), the total liver lesion glycolysis.